Board of Directors Meeting

Investor Presentation

September 2014

Cautionary Note re: Forward Looking Statements

This presentation and oral statements accompanying this presentation contain forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding Amyris’s product pipeline, sizes of markets that may be addressed by

Amyris’s current and potential products, Amyris’s expected product pipeline, expected cash inflows from collaborations and product sales, product revenue pipeline and potential size, financial trends and outlook, operation of production facilities, commercial relationships, and

Amyris’s projected financial results, including cash inflows, operating expenses, earnings and cash payback from a manufacturing plant, that involve risks and uncertainties. These statements and other forward-looking statements that may be provided in the presentation and/or oral statements accompanying it are based on management’s estimates and current expectations and actual results and future events may differ materially due to changes in Amyris’s business and various risks and uncertainties, including those associated with any delays or failures in development, production and commercialization of products, liquidity and ability to fund capital expenditures, Amyris’s reliance on third parties to achieve its goals, and other risks detailed in the

“Risk Factors” section of Amyris’s quarterly report on Form 10-Q filed on August 8, 2014. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

2

Copyright © 2012 Amyris, Inc. All rights reserved.

Non-GAAP Measures

This presentation and oral statements accompanying this presentation contains both GAAP and non-GAAP financial information, because the Company considers non-GAAP information to be a helpful measure to assess its operational performance and for financial and operational decisionmaking. The Company's non-GAAP financial information excludes stock-based compensation, loss on purchase commitments and write off of production assets, depreciation and amortization, gains and losses from changes in fair value of derivatives and debt extinguishment, but adds back accounts receivable, deferred revenue and funding associated with collaborations. A reconciliation of the non-GAAP financial measures presented in this presentation to their GAAP equivalents, is provided in the Company’s Q2’2014 earnings press release dated August 7, 2014.

Additionally, please note during this presentation, we may discuss historical non-GAAP financial measures. For each non-GAAP financial measure discussed a presentation of the most directly comparable GAAP financial measure and a reconciliation of the difference between the non-

GAAP financial measure discussed and the most directly comparable GAAP measure is available in the Investor Relations section of the Company’s website at www.amyris.com

.

3


OVERVIEW

4


The Industrial Bioscience Company

 Proven technology, multiple molecules

 Operating at industrial manufacturing scale

 Differentiated & proven business model

KEY FINANCIAL OUTLOOK

Renewable Products CAGR

Cash Gross Margin Range

Molecules in Pipeline

Average Selling Price per Liter

100% Y-o-Y

50-60%

Over 20

Near $10

AMYRIS BIOREFINERY IN 2 ND YEAR OF OPERATION

COMPANY HIGHLIGHTS

• Founded in 2003 by post-doctoral fellows from the University of California, Berkeley

• Headquartered in the San Francisco Bay

Area and with operations in Brazil

• 395 full-time employees (27% of US employees are PhDs)

• Over 135 issued patents and nearly 300 pending applications

LEADING INVESTORS

BIOLDING investment

5


Milestones of an Industrial Bioscience Company

Signed collaboration agreement with Total

Signed collaboration agreements with

Signed F&F collaboration with IFF

Formed fuels joint venture with Total

Expanded collaboration in farnesene-based polymers

Added multiple new collaborations

Signed collaboration agreement with

Firmenich for F&F

Secured downstream processing facility in the U.S.

Awarded $8MM

DARPA contract

2010

Launched IPO and listed on NASDAQ

2011

Amyris sells diesel in a bus fleet - Brazil Diesel de Cana TM

Further expanded

Firmenich collaboration

2012

First renewable jet fuel demo flight

Sanofi begins production of anti-malarial drug

Amyris-Total renewable jet fuel begins commercialization

2013

First commercial shipment from Brotas

2014

Advanced innovative collaboration to develop ingredients for F&F markets

Amyris-Total demo flight in Airbus 321

(Paris Air Show)

Continued to expand squalane sales

Expanded Firmenich collaboration

Expanded partnership products

VW partners with

Amyris to promote automotive uses of renewable fuels

6


Board of Directors

John Doerr

Patrick Yang

Carole Piwnica

Philippe Boisseau

HH Sheikh Abdullah bin Khalifa Al Thani

B I O L D I N G

I N V E S T M E N T S

Fernando Reinach

John Melo

* Dr. Chua is appointed by Temasek Holdings

7


Nam-Hai Chua*

Geoff Duyk

Neil Williams

Industry Leading Product Portfolio

C O N S U ME R C A R E

COSMETICS AROMAS s q u a l a n e h e m i s q u a l a n e f r a g r a n c e o i l s

P E R F O R MA N C E

MA T E R I A L S p o l y m e r s s o l v e n t s a d h e s i v e s

& c o a t i n g s

R E N E W A B L E

MO B I L I T Y d i e s e l j e t

L U B R I C A N T S e n g i n e t r a n s f o r m e r h y d r a u l i c

8


WHERE WE ARE

9


Four Challenges for Industrial Biosciences

4. Funding

Accessibility

1. Technology

Pace

2. Manufacturing

Scale-Up

3. Top Line

Build-Up

10


Technology Pace

Tested and Proven Platform

Build:

Robotics &

Automation

Test: 100,000 strains/month

 Developed high-throughput strain engineering system to code and screen over 100,000 yeast strains per month at 95% lower cost

 Generated over 600,000 unique farnesene strains in past year, surpassing 3 million strains

 Tested over 5,000 unique strains in actual fermentation to date and now predict 200,000 liter fermentation performance from 2-liter scale tests



Reduced time to target isoprenoid molecule from years to months, with thousands of molecules to be accessed Design based on learnings

11


Technology Pace

Tested and Proven Platform

Target Market

Characteristics

Price & Supply

Volatility

Consumer

Demand for

Naturals

Build Strains

Millions strains per month

Mutagenesis,

Meiosis &

Automated

Strain

Engineering

120,000 strains per month

96-well

Screening

Test Strains and Processes

60 strains per month

0.5 & 2 Liter

Fermentation

2 strains per month

300 Liter

Fermentation

& Recovery

Manufacture

2 to 4 strains per year

200,000 Liter

Fermentation

& Recovery

Need for Higher

Performance at

Competitive Price

LEADING COLLABORATION PARTNERS

12


Cosmetics

• Cosmetic

Emollients

Aromas

• Flavors &

Fragrances

Perf. Materials

• Polymers

• Solvents and Fluids

Fuels

• Diesel

• Jet Fuel

Lubricants

• Base Oils

• Finished Lubricants

Technology Pace:

Robust Strain Pipeline Progress

Amyris “Best of Breed”

Organism Development

 Unique ability to engineer robust strains at industrial scale

 Proprietary processes to validate yeast production capability

 The only “big data” repository of yeast design data

Farnesene

First Generation

Farnesene

Second Generation

Fragrance 1

Fragrance 2

Fragrance 3

13


Manufacturing Scale-Up:

Integrated Scale-Up

Lab

2 L

Pilot Plant

300 L

50

40

30

20

10

0

PRODUCTION COST EVOLUTION

($/L, non-GAAP)

Feedstock currently represents over 50% of the farnesene cost

Lab

2 L scale

14


Pilot Plant

300 L

Demo Plant

5,000 L

Production

6 x 200,000 L

Manufacturing Scale-Up:

Biotech Regulations

●

Application requirements are vast yet the required tests are not explicitly dictated

●

Amyris has developed in-house expertise in risk assessments that have been accepted by CTNBio

●

We’re one of three companies

(the first one) to obtain commercial approval for two strains and maintain CQBs in

Campinas and Brotas

 Amyris’s Farnesene Yeast

 Solazyme’s Algae

 GranBio’s Cellulosic Yeast

15


Handling

Cultivation

Production

Storage

Release

Disposal

Import

Export

Transport

Project

Construction

Transfer

Under Brazil’s 2005 Biosafety Law, regulatory approval is required for every stage of process.

In the case of a microorganism such as GMO yeast, a “CQB” (BioSafety Quality Certificate) is required at every stage until the strain is commercially approved.

Top Line Build-Up:

Current Addressable Market

$1.6T

$212B

Over $1 Trillion Total Addressable

Market Ahead

$123B Over $100 Billion Addressable Market at Current Commercial Performance

$40B

$18B

$9B

$4B

Emollients,

Moisturizers, Film

Formers

F&F Ingredients Elastomers and

Synthetic Rubbers &

Plastic Additives

Auto & Industrial

Lubricants

Bulk Polymers,

Coatings, Adhesives and Polyolefins

Jet Fuel Diesel Fuel

16


Top Line Build-Up:

Diverse Product Mix to Drive Growth

$600

$500

$400

$300

$200

$100

$0

2013 2014 2015 2016 2017

Performance Materials

F&F

Cosmetics

Fuels & Lubes

Collaborations

17


Top-Line Build-Up:

$1B Product Revenue Pipeline

 Pharma

 Nutraceuticals

 Agroscience

 Flavors, Cosmetics,

Polymers

 Multiple Fragrances

 Vitamins

 Solid Farnesene

Rubber*, Elastomers

(e.g. sealants, adhesives)

 Fragrance Ingredients

 3 from Farnesene

 3 from New Strains*

*Development in partnership

 Liquid

Farnesene Rubber*

 Cleaning Solvent

 Hemisqualane

 Jet Fuel

 Diesel

 Squalane

 Patchouli

Opportunity

( Assessment)

Co-Engineering

(Feasibility)

Current Engineering

(Development)

2014 First Revenue

(Launch)

Commercial Business

(Ongoing Revenue)

18


Funding Accessibility:

Over $800M Invested to Date

19



Quality Capital Structure

Leading Equity Holders

350.0

Current Debt Breakdown by Maturity

($ in millions, as of June 2014)

300.0

23.6

250.0

75.0

2.2

200.0

34.0

$306.3M Debt Breakdown by Holder

($ in millions, as of June 2014)

Hercules

Term Loan

Development

30.0

Banks & Project

Financing

31.9

78.8

TOTAL

Convertibles

150.0

100.0

50.0

$53.4 Converts

TOTAL R&D

78.4

$25.0 Converts

Fidelity

6.1

54.6

306.3

Institutional

Holders of

Convertibles

91.3

72.0 Temasek

Convertibles -

30.0

0.2 2.2

Nov'14 Mar'15 Feb'17 Mar'17 Dec'17 Oct'18 Jan'19 Apr'19 May'19 Jul'22

Glycotech Pre-Export

Financing Financing

Hercules

Term Loan

Converts

TOTAL R&D

Fidelity

BNDES

Project

Financing

Tranche I

Converts

Tranche II

Converts

FINEP

Project

Financing

144A

Converts

BNDES

Project

Financing

Total

Debt

NOTE: Equity ownership percentages are based on shares of common stock currently outstanding (excluding convertible notes); Debt breakdown for illustration purposes, loans from Development Banks and Hercules are shown as bullet at maturity, although they have their principal amortizing during their terms. Debt does not include about $2.5 million in working capital.

20



Healthy Financial Trends (Non-GAAP)

Growing Collaboration

Inflows and Product Sales (1)

Reduced Cash

Operating Expenses (1)

$113

$80-85

$85

$73

$70

Cash Used in Operations to Turn Positive (2)

$116

$46

2012

$26

YTD

2013 1H 2014 14 Forecast

Lower Capital

Expenditures

$41

YTD

2012 2013 1H 2014 14 Forecast 2012

Cash Balance Improving

$90

YTD

2013

$27

YTD

1H 2014 14 Forecast

$57

$31

2012

$8

2013

$2

YTD

$8-10

1H 2014 14

Forecast 2012

$8

2013 1H 2014 14 Forecast

(1) For a definition of non-GAAP Collaboration Inflows and Product Sales, refer to the Q2 2014 earnings release

21

(2) Includes non-GAAP Collaboration Inflows and Product Sales less non-GAAP Cost of Products Sold, and non-GAAP R&D and SG&A. Refer to the Q2 earnings release.


Summary

●

Leading industrial synthetic biology technology, transforming how materials are made across all sectors and the technology enabling sustainable growth for the world’s leading brands

●

Only independent company in the sector that has successfully scaled its biotechnology platform at its own industrial scale plant

●

Strong pipeline that supports long-term profitability and growth built on commercialization of first three molecules

●

World class board and management team, supported by some of the leading global investors

●

Strong product revenue growth and consistent cash inflows from multi-year partner collaborations

●

Track record of capital efficient partnerships

●

Capital raise accelerates growth initiatives

●

Strong financial position to support our growth

22


RECENT HIGHLIGHTS

23


Operational Performance

●

Brotas biorefinery achieved best operational performance to date

– Farnesene production and finishing costs continue to decrease

– Fragrance oil production ongoing as planned

●

Met collaboration milestones and expanded with current and new partners

– Natura becomes first cosmetics collaboration

– Braskem joined our isoprene project

●

Received industry validation for our jet fuel, with initial production, shipments completed and sales underway

24


AMYRIS BIOREFINERY IN OPERATION

Commercialization Update

C O N S U ME R C A R E

 Received “quasi-drug” approval for

Neossance® Squalane in Japan, opening significant market for new uses

 Launched Neossance ® Hemisqualane, our second emollient ingredient, with customer interest



Ongoing production and shipments of our first fragrance oil and have strong demand for new fragrance ingredients in

R&D pipeline

P E R F O R MA N C E

MA T E R I A L S

 Braskem joined ongoing isoprene collaboration

 Launched our solvent product to address VOC and performance needs

 Continued progress in liquid polymer product with Kuraray

R E N E W A B L E

MO B I L I T Y

 ASTM spec for jet fuel now includes

10% farnesane blends of Amyris-

Total fuel

 First commercial flight in July with

GOL airlines

 Resumed sales of

Diesel de Cana™ in Brazil

L U B R I C A N T S

 Novvi, our joint venture with

Cosan, validated technology for base oil and lubricants



With funding in place, planned scale production during second half to seed first customers

25


Statement of Earnings

26


Balance Sheet

27


Board of Directors Meeting

Investor Presentation

Cautionary Note re: Forward Looking Statements

Non-GAAP Measures

OVERVIEW

The Industrial Bioscience Company

Milestones of an Industrial Bioscience Company